Influenza A virus protein (IAVP)

Influenza A virus (IAV) proteins comprise the structural and functional components of the virus, including the surface glycoproteins Hemagglutinin (HA) and Neuraminidase (NA), the M2 ion channel, and the internal RNA-dependent RNA polymerase (RdRp) complex (UniProt Consortium, 2023). These proteins are the primary targets for antiviral intervention: HA mediates viral attachment and entry, while NA is an enzyme essential for the release of new virions from the host cell membrane (CDC, 2024). The M2 protein acts as a proton-selective ion channel required for viral uncoating during entry, and the RdRp complex (PA, PB1, and PB2 subunits) is responsible for viral genome replication and transcription (NIH, 2020). Current therapeutic strategies utilize neuraminidase inhibitors like oseltamivir to block viral spread and cap-dependent endonuclease inhibitors like baloxavir marboxil to disrupt viral replication (FDA, 2021). However, the high mutation rate of IAV proteins leads to frequent antigenic drift and the development of drug resistance, posing significant challenges for long-term clinical efficacy and pandemic preparedness (PubMed, 2022). Structural proteins like the Nucleoprotein (NP) also play roles in encapsidating the viral genome and are being explored as novel targets for broad-spectrum antivirals.

Other names

IAV proteinsInfluenza A viral proteinsInfluenza A virus proteome

Inhibition of viral neuraminidase to prevent progeny release; blockade of the M2 proton channel to prevent viral uncoating; and inhibition of the cap-dependent endonuclease activity of the viral polymerase complex to halt mRNA synthesis.